Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Vectibix Assistance Program May Balance Part B Pricing Pressures

Executive Summary

Amgen's pricing strategy for its colorectal cancer therapy Vectibix appears to balance the competing pricing pressures created by Medicare Part B's average sales price-based reimbursement methodology

You may also be interested in...



Avastin For Lung Cancer Will Be Free To Patients Who Beat The Average

Under a Genentech program that caps expenditures for Avastin, the oncologic will be free of charge to patients who continue using the therapy beyond the median duration of treatment for lung cancer

Avastin For Lung Cancer Will Be Free To Patients Who Beat The Average

Under a Genentech program that caps expenditures for Avastin, the oncologic will be free of charge to patients who continue using the therapy beyond the median duration of treatment for lung cancer

Amgen Vectibix Cap Cuts Patient Cost, But Will Payers Balk At High Price?

Amgen announced a program to limit patients' out-of-pocket cost for Vectibix, following FDA approval of panitumumab Sept. 27.

Related Content

UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel